Israeli Company Submits Regulatory Submission for Celiac Treatment
BiolineRx (TLV:BLRX) said last month that it has filed the necessary regulatory submissions to start the first two phases of a trial for BL-7010 — a treatment for Celiac disease — with Finnish health authorities.
BiolineRx (TLV:BLRX) said last month that it has filed the necessary regulatory submissions to start the first two phases of a trial for BL-7010 — a treatment for Celiac disease — with Finnish health authorities. The study will assess single and repeated dosages of the drug in 32 patients.
As quoted in the press release:
“We look forward to commencing the Phase 1/2 clinical study for BL-7010 by the end of the year. The study will be conducted in Finland, which has a significantly higher prevalence of celiac disease than other countries and is a world leader in celiac research,” stated Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx.
“We are very enthusiastic about this unique product, which is generating a lot of excitement from both the scientific and medical communities. Despite the unmet medical need and the huge size of the celiac market, there is no available treatment for the disease apart from a lifelong gluten-free diet, which is extremely difficult to maintain. Since there are also very few products currently in clinical-stage development, we see a significant opportunity in this market for our product.”